Tadalafil + Placebo
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Benign Prostatic Hyperplasia
Conditions
Benign Prostatic Hyperplasia
Trial Timeline
Dec 1, 2011 → Oct 1, 2012
NCT ID
NCT01460342About Tadalafil + Placebo
Tadalafil + Placebo is a phase 3 stage product being developed by Eli Lilly for Benign Prostatic Hyperplasia. The current trial status is completed. This product is registered under clinical trial identifier NCT01460342. Target conditions include Benign Prostatic Hyperplasia.
What happened to similar drugs?
10 of 20 similar drugs in Benign Prostatic Hyperplasia were approved
Approved (10) Terminated (2) Active (8)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (14)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01865084 | Phase 3 | Terminated |
| NCT01460342 | Phase 3 | Completed |
| NCT01152190 | Phase 3 | Completed |
| NCT01130532 | Approved | Completed |
| NCT01026818 | Approved | Completed |
| NCT00848081 | Phase 3 | Completed |
| NCT00855582 | Phase 3 | Completed |
| NCT00836693 | Phase 3 | Completed |
| NCT00422734 | Phase 3 | Completed |
| NCT00538564 | Phase 2 | Withdrawn |
| NCT00386009 | Phase 2 | Completed |
| NCT00547625 | Phase 2 | Completed |
| NCT00382135 | Approved | Completed |
| NCT00381732 | Phase 3 | Completed |
Competing Products
20 competing products in Benign Prostatic Hyperplasia